QUE Oncology is focused on unlocking the significant potential of its lead product Q-122 in development as a non-hormonal treatment for moderate to severe vasomotor symptoms (hot flashes and night sweats) in postmenopausal women, and in cancer patients receiving hormone therapy.
QUE was formed in 2013 through a joint venture between Emory University in Atlanta and the University of Queensland (UQ) research commercialization company, UniQuest.
QUE is backed by venture capital groups, led by Australia’s Medical Research Commercialization Fund (MRCF) and Uniseed.
QUE is a clinical stage company that has recently completed a randomized, double-blind, placebo-controlled Phase 2 trial for the treatment of hot flashes in breast cancer patients across Australia, New Zealand, and the US. This study met its primary efficacy endpoint and exhibited a very well tolerated profile.